These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25510341)

  • 21. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
    Gliniak B; Le T
    Cancer Res; 1999 Dec; 59(24):6153-8. PubMed ID: 10626806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WGCNA reveals key gene modules regulated by the combined treatment of colon cancer with PHY906 and CPT11.
    Xing S; Wang Y; Hu K; Wang F; Sun T; Li Q
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32812032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.
    Lam W; Jiang Z; Guan F; Huang X; Hu R; Wang J; Bussom S; Liu SH; Zhao H; Yen Y; Cheng YC
    Sci Rep; 2015 Mar; 5():9384. PubMed ID: 25819872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.
    Cheng KW; Tseng CH; Tzeng CC; Leu YL; Cheng TC; Wang JY; Chang JM; Lu YC; Cheng CM; Chen IJ; Cheng YA; Chen YL; Cheng TL
    Pharmacol Res; 2019 Jan; 139():41-49. PubMed ID: 30391354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy.
    Liu SH; Cheng YC
    J Ethnopharmacol; 2012 Apr; 140(3):614-23. PubMed ID: 22326673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New approaches to prevent intestinal toxicity of irinotecan-based regimens.
    Alimonti A; Gelibter A; Pavese I; Satta F; Cognetti F; Ferretti G; Rasio D; Vecchione A; Di Palma M
    Cancer Treat Rev; 2004 Oct; 30(6):555-62. PubMed ID: 15325035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.
    Huisman SA; de Bruijn P; Ghobadi Moghaddam-Helmantel IM; IJzermans JN; Wiemer EA; Mathijssen RH; de Bruin RW
    Br J Pharmacol; 2016 Mar; 173(5):804-14. PubMed ID: 26332723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.
    Alvarenga EM; Souza LK; Araújo TS; Nogueira KM; Sousa FB; Araújo AR; Martins CS; Pacífico DM; de C Brito GA; Souza EP; Sousa DP; Medeiros JV
    Chem Biol Interact; 2016 Dec; 260():129-140. PubMed ID: 27838229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
    Cao S; Black JD; Troutt AB; Rustum YM
    Cancer Res; 1998 Aug; 58(15):3270-4. PubMed ID: 9699654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K; Hagiwara T; Watanabe K; Onose S; Yoshida S; Kumazawa E; Nagai E; Kamataki T
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
    Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
    FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
    Guo S; Zhang X; Gan L; Zhu C; Gan Y
    J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.
    Zwolinska-Wcislo M; Krzysiek-Maczka G; Ptak-Belowska A; Karczewska E; Pajdo R; Sliwowski Z; Urbanczyk K; Drozdowicz D; Konturek SJ; Pawlik WW; Brzozowski T
    J Physiol Pharmacol; 2011 Jun; 62(3):357-68. PubMed ID: 21893697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
    Kumazawa E; Jimbo T; Ochi Y; Tohgo A
    Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer.
    Xiao B; Viennois E; Chen Q; Wang L; Han MK; Zhang Y; Zhang Z; Kang Y; Wan Y; Merlin D
    ACS Nano; 2018 Jun; 12(6):5253-5265. PubMed ID: 29860836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).
    Zhang W; Saif MW; Dutschman GE; Li X; Lam W; Bussom S; Jiang Z; Ye M; Chu E; Cheng YC
    J Chromatogr A; 2010 Sep; 1217(37):5785-93. PubMed ID: 20696432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats.
    Lin XB; Farhangfar A; Valcheva R; Sawyer MB; Dieleman L; Schieber A; Gänzle MG; Baracos V
    PLoS One; 2014; 9(1):e83644. PubMed ID: 24454707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of cells expressing OLFM4 and LGR5 mRNA by in situ hybridization in the yolk sac and small intestine of embryonic and early post-hatch chicks.
    Zhang H; Wong EA
    Poult Sci; 2018 Feb; 97(2):628-633. PubMed ID: 29155957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.